Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06177041
Status:
RECRUITING
Last Update Posted:
2024-02-28
First Post:
2023-12-11
Brief Title:
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin CLDN 182-Positive HER2-Negative PD-L1 CPS5 Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction GEJ Adenocarcinoma
Sponsor:
FutureGen Biopharmaceutical Beijing Co Ltd
Organization:
FutureGen Biopharmaceutical Beijing Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-25
Start Date Type:
ACTUAL
Primary Completion Date:
2027-01-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-04-11
Completion Date Type:
ESTIMATED
First Submit Date:
2023-12-11
First Submit QC Date:
December 11 2023
Study First Post Date:
2023-12-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-25
Last Update Post Date:
2024-02-28
Last Update Post Date Type:
ACTUAL